Search
Toremifene
go.drugbank.com/drugs/DB00539ApprovedInvestigational[A256928] Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however … , it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag is currently in phase III development in various European countries including Austria, Belgium, Germany, and the UK [A36730]. … In September 2015, lusutrombopag received its first global approval in Japan to reduce the need for platelet transfusion in adults with chronic liver disease and thrombocytopenia who are schedule to undergo
Carob
go.drugbank.com/drugs/DB10852ApprovedCarob allergenic extract is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household settingFluvastatin
go.drugbank.com/drugs/DB01095ApprovedInvestigationalHMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. … It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class.
Meningococcal polysaccharide vaccine group W-135
go.drugbank.com/drugs/DB13887ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.
Mixtures: MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADET, MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADETOlutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigationalin 2-hydroxyglutarate (2-HG), a metabolite that participates in tumerogenesis. … Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022.
Prednisolone acetate
go.drugbank.com/drugs/DB15566ApprovedInvestigationalVet approvedPrednisolone acetate is a [prednisolone] molecule bound to an acetate functional group by an ester bond.[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigationalElafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis. … [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878]
Regorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalApproved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. … Regorafenib is an orally-administered inhibitor of multiple kinases.
Fenofibrate
go.drugbank.com/drugs/DB01039ApprovedInvestigationalFenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil].[A185954] Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia. … [L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.[L8585]